On Monday, Goldman Sachs reaffirmed its Buy rating and $52.00 stock price target for CG Oncology (NASDAQ:CGON). The firm's analyst has been actively engaged in discussions with investors regarding the upcoming final results from the Phase 3 BOND-003 study of cretostimogene, a drug designed for the treatment of BCG-unresponsive, high-risk non-muscle invasive bladder cancer (NMIBC).
Investors have expressed interest in understanding how to evaluate and compare the durability of cretostimogene to TAR-200, based on Kaplan-Meier estimates. Moreover, there have been conversations about proposed changes by Johnson & Johnson to the FDA's draft guidance on study designs within NMIBC, as well as potential administration requirements for BSL2.
The analyst has addressed these topics, noting that cretostimogene is viewed as potentially the best in its category, considering factors such as safety, efficacy, and ease of administration. However, the differentiation between cretostimogene and TAR-200 hinges on data related to the drug's durability.
Looking ahead, there is a growing interest in long-term durability data, which is expected to become clearer with the forthcoming results, including data on the 24-month complete response rate. The majority of the data contributing to the 12-month complete response rate has already been reported, so the focus is now on longer-term outcomes as a potential driver for an upside in CG Oncology's share value.
In other recent news, CG Oncology has been the subject of multiple analyst reports focusing on its drug, cretostimogene. Goldman Sachs reaffirmed a Buy rating on the company, maintaining a $52 target.
The firm noted cretostimogene's 43% 12-month complete response rate and its potential to improve. H.C. Wainwright also maintained its Buy rating and a $75 target, emphasizing the strong safety profile of cretostimogene, with 0% Grade 3+ treatment-related adverse events and discontinuations.
Roth/MKM issued a Buy rating for CG Oncology with a $65 target, citing the potential of cretostimogene to capture market share from competing treatments due to its tolerability. The firm also highlighted the drug's efficacy in treating high-risk non-muscle invasive bladder cancer.
These recent developments underscore the ongoing interest in CG Oncology's work in the oncology space. It is worth noting that these evaluations come in light of the company's competitor releasing preliminary data from its LEGEND study, which demonstrated a decreasing efficacy over time.
Despite this, analysts from Goldman Sachs suggest that cretostimogene's figures could potentially improve. The final analysis from CG Oncology's BOND-003 trial is expected by the end of 2024.
InvestingPro Insights
To complement the analysis of CG Oncology's (NASDAQ:CGON) potential in the NMIBC treatment space, let's examine some key financial metrics and insights from InvestingPro.
According to InvestingPro data, CG Oncology's market capitalization stands at $2.44 billion, reflecting investor confidence in the company's prospects. The company's revenue growth is particularly noteworthy, with a remarkable 172.68% increase in quarterly revenue as of Q1 2024. This substantial growth aligns with the positive outlook on cretostimogene's potential in the market.
InvestingPro Tips highlight that analysts anticipate sales growth in the current year, which supports the optimistic stance on the company's future performance. Additionally, CG Oncology holds more cash than debt on its balance sheet, providing financial flexibility to support ongoing research and development efforts.
However, it is important to note that the company is not currently profitable, with a negative gross profit margin in the last twelve months. This is not uncommon for biotech companies in the development stage, especially those with promising drug candidates like cretostimogene.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips that could provide deeper insights into CG Oncology's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.